Erythropoietin in Medical Technology
Navigation Links
Erythropoietin in Medical Technology
... for the rights
to a use patent on Recombinant erythropoietin ("rHuEPO") for the prolongation
of multiple ... second or third quarter of 2009.
ABOUT erythropoietin (EPO)
erythropoietin (EPO) is a glycoprotein cytokine produced mainly ...
... associated with neutralizing antibodies to erythropoietin have been reported in patients treated with ... for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT ... Treatment of patients with grossly elevated serum erythropoietin levels (e.g., >200 mUnits/mL) is not ...
... associated with neutralizing antibodies to erythropoietin have been reported in patients treated with ... for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, ... Treatment of patients with grossly elevated serum erythropoietin levels (e.g., >200 mUnits/mL) is not ...
... thus effectively treating their anemia without receiving any injections of erythropoietin (EPO) during this period. One of the patients received his last EPO ... based on this technology: EPODURE - producing erythropoietin (EPO) to treat anemia INFRADURE - producing interferon-alpha ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... or prevent chemotherapy-induced anemia and to maintain or stimulate erythropoietin function or synthesis. Erythropoiesis is the process by which red blood cells are produced, and involves the release of a hormone called erythropoietin that stimulates the red bone marrow to begin red blood cell production. ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... HCV SPRINT-1 study, anemia occurred in approximately half of the patients in the boceprevir arms and over a third of patients in the control arm. erythropoietin (EPO) supplementation was allowed in the study at the discretion of the investigator and was used by 26 percent of patients in the control arm and ...
... ongoing Phase I/II clinical trial, a one-time administration of EPODURE, producing and delivering the low dose of 18-25 IU/kg/day of the protein erythropoietin (EPO), was sufficient to sustain therapeutic elevation of hemoglobin in most patients. The earliest patients to receive treatment have shown ...
... in their anemia. This improvement was larger than the improvement in fatigue reported in a separate study of anemic cancer patients treated with erythropoietin (EPO). Furthermore, in contrast to the improvement in fatigue of anemic cancer patients treated with EPO which occurred only when anemia was ...
... additional later stage clinical trials. About Hematide Hematide is a novel synthetic, pegylated peptidic compound that binds to and activates the erythropoietin receptor and acts as an erythropoiesis stimulating agent. The product is being developed for treatment of anemia in patients with chronic renal ...
... attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. 1. Development of a Long-Acting erythropoietin by Fusing the Carboxyl- Terminal Peptide of Human Chorionic Gonadotropin b-Subunit to the Coding Sequence of Human Erythropoietin," Fuad ...
... In addition, Modigene's long-acting erythropoietin has demonstrated, in a pre-clinical animal model ... over Amgen Inc.'s Aranesp(R), a long-acting erythropoietin with reported sales of $4.1 billion in 2006, out ... total estimated EPO market size of $11.7 billion. erythropoietin is prescribed for the treatment of anemia. "We ...
... with the hemodialysis patient population. About Hematide Hematide is a novel synthetic, pegylated peptide that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in chronic kidney disease and cancer. About Affymax, Inc. Affymax, Inc. is a ...
... shortened survival and increased the risk of death in cancer patients. Pure Red Cell Aplasia (PRCA) has been observed in patients treated with erythropoietin therapy. However, PRCA has not been observed with MIRCERA in clinical trials to date. About Roche Hoffmann-La Roche Inc. (Roche), based in ...
... optimizing anemia management in their patients." About Hematide Hematide is a novel synthetic, pegylated peptide that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in chronic kidney disease and cancer. About Affymax, Inc. Affymax, Inc. is a ...
... of renal anaemia, can be successfully treated with MIRCERA on a simple twice-monthly dosing schedule. About MIRCERA MIRCERA, a continuous erythropoietin receptor activator, is the first of a new class of long-acting chemically synthesized erythropoiesis-stimulating agents (ESAs) having reached ...
... multiple myeloma (RRMM) -- P. Sonneveld; Abstract #8023; June 3, 2007; 3:00-3:15pm; McCormick Place Convention Center, E354b An analysis of erythropoietin (EPO) and VTE in MM patients treated with anthracycline-based chemotherapy and the immunomodulatory agent thalidomide -- R. Baz; Abstract #8107; ...
... for approval of Thalidomide Pharmion as a first line therapy for multiple myeloma in Europe. Data Presented Saturday, June 2 An analysis of erythropoietin (EPO) and VTE in MM patients treated with anthracycline-based chemotherapy and the immunomodulatory agent thalidomide -- R. Baz; Abstract #8107; ...
... to outpatient intervention). About Hematide Hematide is a novel synthetic, pegylated peptidic compound that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in patients with chronic renal failure and cancer patients receiving chemotherapy. ...
... associated with neutralizing antibodies to erythropoietin have been reported in patients treated with ... for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT ... Treatment of patients with grossly elevated serum erythropoietin levels (e.g., >200 mUnits/mL) is not ...
... associated with neutralizing antibodies to erythropoietin have been reported in patients treated with ... for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, ... Treatment of patients with grossly elevated serum erythropoietin levels (e.g., >200 mUnits/mL) is not ...
... thus effectively treating their anemia without receiving any injections of erythropoietin (EPO) during this period. One of the patients received his last EPO ... based on this technology: EPODURE - producing erythropoietin (EPO) to treat anemia INFRADURE - producing interferon-alpha ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... or prevent chemotherapy-induced anemia and to maintain or stimulate erythropoietin function or synthesis. Erythropoiesis is the process by which red blood cells are produced, and involves the release of a hormone called erythropoietin that stimulates the red bone marrow to begin red blood cell production. ...
Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients with chronic renal failure receiving ... to perform assays for binding and neutralizing antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently ...
... HCV SPRINT-1 study, anemia occurred in approximately half of the patients in the boceprevir arms and over a third of patients in the control arm. erythropoietin (EPO) supplementation was allowed in the study at the discretion of the investigator and was used by 26 percent of patients in the control arm and ...
... ongoing Phase I/II clinical trial, a one-time administration of EPODURE, producing and delivering the low dose of 18-25 IU/kg/day of the protein erythropoietin (EPO), was sufficient to sustain therapeutic elevation of hemoglobin in most patients. The earliest patients to receive treatment have shown ...
... in their anemia. This improvement was larger than the improvement in fatigue reported in a separate study of anemic cancer patients treated with erythropoietin (EPO). Furthermore, in contrast to the improvement in fatigue of anemic cancer patients treated with EPO which occurred only when anemia was ...
... additional later stage clinical trials. About Hematide Hematide is a novel synthetic, pegylated peptidic compound that binds to and activates the erythropoietin receptor and acts as an erythropoiesis stimulating agent. The product is being developed for treatment of anemia in patients with chronic renal ...
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
... of inducible transcription factors. JAK2 plays a pivotal role in the cellular response to growth factors that drive blood cell expansion, including erythropoietin and thrombopoietin. Mutational activation of JAK2 is observed in the majority of patients with polycythemia vera, essential thrombocythemia ...Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
... administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic benefits of recombinant erythropoietin treatments. Rockwell has licensed the exclusive world-wide rights to SFP and is seeking FDA market approval. Patents for SFP have been secured in ...... attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. 1. Development of a Long-Acting erythropoietin by Fusing the Carboxyl- Terminal Peptide of Human Chorionic Gonadotropin b-Subunit to the Coding Sequence of Human Erythropoietin," Fuad ...
Researchers Urge Caution in Using ESAs for Cancer-Related Anemia
... stronger effects on these receptors than natural erythropoietin does. If so, then it is possible that ESAs may ... studies at their laboratory suggest that erythropoietin may have abnormal effects on the erythropoietin receptors in cultured tumor cells. If this also ...... In addition, Modigene's long-acting erythropoietin has demonstrated, in a pre-clinical animal model ... over Amgen Inc.'s Aranesp(R), a long-acting erythropoietin with reported sales of $4.1 billion in 2006, out ... total estimated EPO market size of $11.7 billion. erythropoietin is prescribed for the treatment of anemia. "We ...
... with the hemodialysis patient population. About Hematide Hematide is a novel synthetic, pegylated peptide that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in chronic kidney disease and cancer. About Affymax, Inc. Affymax, Inc. is a ...
... shortened survival and increased the risk of death in cancer patients. Pure Red Cell Aplasia (PRCA) has been observed in patients treated with erythropoietin therapy. However, PRCA has not been observed with MIRCERA in clinical trials to date. About Roche Hoffmann-La Roche Inc. (Roche), based in ...
Aranesp ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
... period. Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients treated with Aranesp. This has been reported predominantly in patients with CRF receiving Aranesp by subcutaneous ...... optimizing anemia management in their patients." About Hematide Hematide is a novel synthetic, pegylated peptide that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in chronic kidney disease and cancer. About Affymax, Inc. Affymax, Inc. is a ...
... of renal anaemia, can be successfully treated with MIRCERA on a simple twice-monthly dosing schedule. About MIRCERA MIRCERA, a continuous erythropoietin receptor activator, is the first of a new class of long-acting chemically synthesized erythropoiesis-stimulating agents (ESAs) having reached ...
... multiple myeloma (RRMM) -- P. Sonneveld; Abstract #8023; June 3, 2007; 3:00-3:15pm; McCormick Place Convention Center, E354b An analysis of erythropoietin (EPO) and VTE in MM patients treated with anthracycline-based chemotherapy and the immunomodulatory agent thalidomide -- R. Baz; Abstract #8107; ...
... for approval of Thalidomide Pharmion as a first line therapy for multiple myeloma in Europe. Data Presented Saturday, June 2 An analysis of erythropoietin (EPO) and VTE in MM patients treated with anthracycline-based chemotherapy and the immunomodulatory agent thalidomide -- R. Baz; Abstract #8107; ...
... to outpatient intervention). About Hematide Hematide is a novel synthetic, pegylated peptidic compound that binds to and activates the erythropoietin receptor. The product is being developed for treatment of anemia in patients with chronic renal failure and cancer patients receiving chemotherapy. ...
Other ContentsthromboembolismthromboembolismthromboembolismthrombolyticthrombolyticthrombophlebitisthrombosisthrombosisthrombosisthrombosisthrombosisteststeststeststeststeststeststeststeststeststestsfunctionfunctionfunctionfunctionfunctionfunctionfunctionfunctionfunctionfunctionthrushsuckingsuckingsuckingsuckingOther TagsArgArgArgArgArgArgArgdesdesdesdesdesdesdesTetRTetRTetROther Tagscool 2cool 3cool 4doors 2doors 3now 2now 3now 4now 5now 6now 7now 8now 9now 10
(Date:11/24/2009)...derstanding how sounds associated with Navy sonar ... they hear it at all. , The same type of large i...etect flaws in the space shuttle,s behemoth solid ...side the giant head of a whale. The scans are prov...le,s hearing anatomy using a breakthrough method d...
(Date:11/24/2009)...09) -- The Wildlife Conservation Society (WCS) ann...ining population of Siberian tigers has likely dec...hing and habitat loss. , WCS says th...t needs to be done to protect remaining population... report was released by the Siberian Tiger Monitor...
(Date:11/23/2009)...idence that the "synergistic" effect of early-life...n and indoor endotoxin causes more harm to develop..., Environmental health scientists at the Univers...own that children exposed to both high levels of t...ng early life are six times more likely to experie...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Report shows dramatic decline in Siberian tigers 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Teen Girls at Higher Risk for STDs 3A Report 61460 1Teen Girls at Higher Risk for STDs 3A Report 61460 2LeapFish and Make a Wish Foundation Join Forces to Raise 2410 000 and Tweet an Ill Child 26apos 3Bs Wish True 61455 1LeapFish and Make a Wish Foundation Join Forces to Raise 2410 000 and Tweet an Ill Child 26apos 3Bs Wish True 61455 2Georgia Power Centers for Disease Control and Prevention Forge Green Energy Partnership 61450 1Georgia Power Centers for Disease Control and Prevention Forge Green Energy Partnership 61450 2(Date:11/26/2009)...s & Ennis, P.A. is offering free nationwide co...in birth control pills who have suffered a Deep Ve...eart Attack or other related cardiac issues or had...ee at 1-800-856-6405 or go to the firm’s web...online case evaluation form. , ...
(Date:11/25/2009)...25/PRNewswire-FirstCall/-- OnyxPharmaceuticals,In...osttwoinvestoreventsinDecember: ,, ASHBriefin... ,, Principalinvestigatorswilldiscussdataprese...actorymultiplemyeloma,asfeaturedatthe51stAmericanS...nNewOrleans,LA.Theteleconferencewillbeginat9:00a.m...
(Date:11/25/2009)...5/PRNewswire/--Thanksgivingmealswillbedeliveredtoa...eachareathankstoFaithInAction/VolunteerActionforAg...isionofSCANHealthPlan.Formorethan17yearstheseorgan...armThanksgivingmealstoseniorsinneedinLongBeach,Lak...ndingcities. ,, "Ourwarmholidaymealsaredelivere...
(Date:11/25/2009)...Newswire/--TheBayAreaAirQualityManagementDistricti... Air Alert forThursday,November26,2009whichba...uel,bothindoorsandoutdoors. ,, "Cold,stillweath...dJackBroadbent,executiveofficeroftheAirDistrict."W...rneighborsandfellowcommunitymembersthisThanksgivin...
(Date:11/25/2009)...nce of a statistically significant survival benefi...rogen receptor (ER)-positive tumors had high level...R-alpha S118-P), according to a brief communicatio...the National Cancer Institute . , Approximately ...n. Preclinical studies have shown that ER-alpha S1...
Breaking Medicine News(10 mins):Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2[0] Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills[0] Onyx Pharmaceuticals Announces December 2009 Investor Events[0] SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors[0] Winter Spare the Air Alert in Effect for Thursday, November 26, 2009[1] News brief: Estrogen receptor-alpha, breast cancer patients and tamoxifen response
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |